Eli Lilly and Company reported a significant increase in its second-quarter revenue, reaching $23 billion, a 48% year-over-year growth. This surge was primarily driven by its GLP-1 drugs, Mounjaro and Zepbound, which generated $10 billion and $5 billion respectively. The company also highlighted promising results for its next-generation weight-loss drug, retatrutide, with plans to seek FDA approval in 2027 after clinical trials showed an average weight loss of over 20%. Additionally, the report touched upon a study where a cannabis-derived drug, Dronabinol, showed promise in reducing nightmares for PTSD patients. AI
RANK_REASON Company earnings report detailing significant revenue growth and promising drug trial results. [lever_c_demoted from significant: ic=1 ai=0.0]
- Apnimed
- AstraZeneca
- Charité
- CSPC Pharmaceutical Group
- Democratic Republic Of Congo
- Eli Lilly and Company
- Nature medicine
- retatrutide
- tetrahydrocannabinol
- tirzepatide
- United States Food and Drug Administration
- World Health Organization
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
